Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Medication Combined with Behavior Therapy Works Best for ADHD Children

09.05.2005


Research is first to test effectiveness of a new ’patch’ for treating ADHD



A new University at Buffalo study of treatments for children with attention deficit hyperactivity disorder (ADHD) has found that combining behavior modification therapy with medication is the most effective way to improve the behavior of many ADHD children.
In fact, when the two are combined, the study showed, the amount of medication required to achieve the same results as use of medication alone can be reduced by two-thirds.

"One of the major findings of the study is that when using behavior modification, you can get away with tiny, tiny doses of medication, much lower than previously thought," said ADHD researcher William E. Pelham, Jr., University at Buffalo Distinguished Professor in the Department of Psychology, UB College of Arts and Sciences and UB School of Medicine and Biomedical Sciences.



The study is the first to test the effectiveness of a new drug treatment, a methylphenidate (MPH) patch. Methylphenidate is the stimulant used in pill form by ADHD drugs Concerta and Ritalin.

The study is published in the May issue of Experimental and Clinical Psychopharmacology. It was funded by a grant from Noven Pharmaceuticals. Shire Pharmaceuticals Group, which purchased the rights to the MPH patch from Noven, will seek FDA approval for the MPH patch in 2006.

Twenty-seven children with ADHD, ages 6 to 12, participated in the study, conducted at the University at Buffalo’s Summer Treatment Program for children with ADHD. Pelham and co-researchers assessed the effects of behavior modification, the MPH patch and a placebo on the children in classroom and organized play settings, and through use of parental behavior ratings.

The researchers found that when used alone, the MPH patch and behavior modification therapy were equally effective treatments. The MPH patch was effective in all doses tested, with few reports of side effects and good wear characteristics.

Combined treatment -- using a very low dose of the MPH patch with behavior modification -- was superior to either treatment alone, however. "The patch used with behavior modification caused the greater amount of improvement in the behavior of the children," says Pelham, who helped develop Concerta and who has conducted many other trials involving other stimulant drugs.

Significantly, the study also found that with combined treatment children required much lower doses of medication -- as much as 67 percent lower -- to achieve the same effects as high doses of medication used alone.

Lower dosages of medication lowers the risk of long-term drug side effects, which studies have shown to include loss of appetite and stunting of growth, Pelham points out. "Long-term side effects of ADHD drugs are almost always related to dosage," he says. "If you want to lower a child’s dosages daily and throughout their lifetime, the best way to do that is to combine the medication with behavior modification."

According to Pelham, the MPH patch’s dosage flexibility potentially makes it ideal for administering lower dosages of methylphenidate in combination with behavior modification. The MPH patch can be applied to a child for short periods during the course of the day. The most commonly used pill forms of methylphenidate, which last for 12 hours, do not offer such flexibility, Pelham says.

"The patch enables users to use less medication for short time periods, and that’s good in my opinion," Pelham says. "I think parents are becoming more concerned about the safety of medications than they have been in the past."

The study is the first comparison study of medication and behavior modification to control for the presence and absence of behavior modification that is received by a child daily from parents, teachers, siblings or peers, according to Pelham. As such, the study is the first to accurately isolate the effects of medication and behavior modification treatments, Pelham says.

"There’s so much behavior modification that goes on naturally in the world that unless you do a study where you guarantee that all of it is taken away you underestimate the effect of behavior modification because it’s always there," Pelham says.

"This study shows that when you control for those outside factors, you get effects of behavior modification that are just as big as high doses of medication."

The study’s results, Pelham says, should send a clear message to parents of children with ADHD. "You definitely should be using behavior modification," he says. "You’ll be giving your children much lower doses of medication over their lifetimes if you combine behavior modification with medication."

The study’s co-investigators were Lisa Burrows-MacLean, Elizabeth M. Gnagy, Gregory A. Fabiano, Erika K. Coles, Katy E. Tresco, Anil Chacko, Brian T. Wymbs, Amber L. Wienke, Kathryn S. Walker and Martin T. Hoffman from the UB Center for Children and Families.

The University at Buffalo is a premier research-intensive public university, the largest and most comprehensive campus in the State University of New York.

John Della Contrada | EurekAlert!
Further information:
http://www.buffalo.edu

More articles from Health and Medicine:

nachricht The end of pneumonia? New vaccine offers hope
23.10.2017 | University at Buffalo

nachricht Scientists track ovarian cancers to site of origin: Fallopian tubes
23.10.2017 | Johns Hopkins Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Salmonella as a tumour medication

HZI researchers developed a bacterial strain that can be used in cancer therapy

Salmonellae are dangerous pathogens that enter the body via contaminated food and can cause severe infections. But these bacteria are also known to target...

Im Focus: Neutron star merger directly observed for the first time

University of Maryland researchers contribute to historic detection of gravitational waves and light created by event

On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...

Im Focus: Breaking: the first light from two neutron stars merging

Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.

Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....

Im Focus: Smart sensors for efficient processes

Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).

When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...

Im Focus: Cold molecules on collision course

Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.

How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

3rd Symposium on Driving Simulation

23.10.2017 | Event News

ASEAN Member States discuss the future role of renewable energy

17.10.2017 | Event News

World Health Summit 2017: International experts set the course for the future of Global Health

10.10.2017 | Event News

 
Latest News

Microfluidics probe 'cholesterol' of the oil industry

23.10.2017 | Life Sciences

Gamma rays will reach beyond the limits of light

23.10.2017 | Physics and Astronomy

The end of pneumonia? New vaccine offers hope

23.10.2017 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>